Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

October 30, 2007 07:00 ET

Novadaq Announces Third Quarter 2007 Conference Call and Webcast

TORONTO, ONTARIO--(Marketwire - Oct. 30, 2007) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical
imaging systems and image guided therapies for the operating room, will
host a conference call and live webcast to discuss the financial results
for the third quarter ended September 30, 2007.



Date: November 5, 2007

Time: 4:30 pm, Eastern Time

Dial in number: 416-644-3418 or 1-800-732-6179

Taped replay: 416-640-1917 or 1-877-289-8525 (Available until
November 12th, 2007)

Code number: 21251726

Webcast: A live audio webcast of the call will be available at
www.novadaq.com.
Please connect to this website at least 15 minutes prior
to the conference call to ensure adequate time for any
software download that may be needed to hear the
webcast. The webcast will be archived for 90 days.


About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary ICG imaging systems can be used to visualize blood
vessels, nerves and the lymphatic system during a variety of surgical
procedures. Novadaq's SPY® Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of heart bypass surgery. The SPY System
is expandable to include upgrade kits for use during other surgeries such as
plastic, reconstructive and organ transplant surgery allowing surgeons to
evaluate blood flow and tissue and organ perfusion. In addition, SPY is ideal
for use during urological procedures enabling surgeons to visualize vessels,
tumors, the lymphatic system and potentially nerve bundles. Novadaq's OPTTX®
System is aimed at the diagnosis, evaluation and treatment of wet Age-related
Macular Degeneration (AMD) by using the same core imaging technology that is
used in the SPY Imaging System. Novadaq also offers the FDA approved
PINPOINT™ endoscopic system for visualizing native tissue fluorescence
which allows surgeons to differentiate between healthy and cancerous tissue in
the lung during thoracic surgery. Novadaq is also the exclusive United States
distributor of PLC Medical's CO(2) HEART LASER™ System for TMR
(Trans-Myocardial Revascularization). For more information, please visit the
company's website at www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, the
market entry (and timing thereof) of additional suppliers of ICG, market
acceptance and future commitments for the PINPOINT endoscopic imaging system
and other Novadaq devices. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at www.novadaq.com.

Contact Information